CA2614105A1 - Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents - Google Patents
Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents Download PDFInfo
- Publication number
- CA2614105A1 CA2614105A1 CA002614105A CA2614105A CA2614105A1 CA 2614105 A1 CA2614105 A1 CA 2614105A1 CA 002614105 A CA002614105 A CA 002614105A CA 2614105 A CA2614105 A CA 2614105A CA 2614105 A1 CA2614105 A1 CA 2614105A1
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- oxazolidine
- compound
- carboxamide
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Oxazolidinone carboxamides Chemical class 0.000 title claims description 39
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 5
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title description 4
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- MZWNHSKBTFAJMO-SNVBAGLBSA-N (5r)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)N)CN1C(C=C1F)=CC(F)=C1N1CC(F)C1 MZWNHSKBTFAJMO-SNVBAGLBSA-N 0.000 claims description 4
- QLFYBIHUZTVYLZ-LLVKDONJSA-N (5r)-3-[3,5-difluoro-4-(3-methoxyazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound C1C(OC)CN1C1=C(F)C=C(N2C(O[C@H](C2)C(N)=O)=O)C=C1F QLFYBIHUZTVYLZ-LLVKDONJSA-N 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- IRFVRADPPWSDRO-SECBINFHSA-N (5r)-3-[3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)N)CN1C(C=C1F)=CC(F)=C1N1CC(O)(C(F)(F)F)C1 IRFVRADPPWSDRO-SECBINFHSA-N 0.000 claims description 3
- AFJCEJPQZPATJN-YHBRXECLSA-N (5r)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)N)CN1C(C=C1F)=CC=C1C1CC(O)C1 AFJCEJPQZPATJN-YHBRXECLSA-N 0.000 claims description 3
- HFHWCXDIAHKKFS-QDPIBXHXSA-N (5r)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound C1C(OC)CC1C1=CC=C(N2C(O[C@H](C2)C(N)=O)=O)C=C1F HFHWCXDIAHKKFS-QDPIBXHXSA-N 0.000 claims description 3
- PYNOLZSCEJHBJO-SECBINFHSA-N (5r)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)N)CN1C(C=C1F)=CC(F)=C1N1CC(F)(F)C1 PYNOLZSCEJHBJO-SECBINFHSA-N 0.000 claims description 3
- NJZXHNCOJMZNMA-SNVBAGLBSA-N (5r)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)N)CN1C(C=C1F)=CC=C1N1CC(F)(F)C1 NJZXHNCOJMZNMA-SNVBAGLBSA-N 0.000 claims description 3
- SUAVXAFJFKRJMB-LLVKDONJSA-N (5r)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-n-methyl-2-oxo-1,3-oxazolidine-5-carboxamide Chemical compound O=C1O[C@@H](C(=O)NC)CN1C(C=C1F)=CC=C1N1CC(F)(F)C1 SUAVXAFJFKRJMB-LLVKDONJSA-N 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- 241000588621 Moraxella Species 0.000 claims description 3
- 241000295644 Staphylococcaceae Species 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241001112696 Clostridia Species 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 208000001860 Eye Infections Diseases 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 2
- 241000186367 Mycobacterium avium Species 0.000 claims description 2
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 208000011323 eye infectious disease Diseases 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 239000000243 solution Substances 0.000 description 77
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 238000012746 preparative thin layer chromatography Methods 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 101150041968 CDC13 gene Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 7
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- MCVFFRWZNYZUIJ-UHFFFAOYSA-M lithium;trifluoromethanesulfonate Chemical compound [Li+].[O-]S(=O)(=O)C(F)(F)F MCVFFRWZNYZUIJ-UHFFFAOYSA-M 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- YKNYRRVISWJDSR-GSVOUGTGSA-N methyl (2r)-oxirane-2-carboxylate Chemical compound COC(=O)[C@H]1CO1 YKNYRRVISWJDSR-GSVOUGTGSA-N 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000006772 olefination reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- NTIFCJREGXVJAG-UHFFFAOYSA-N 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-one Chemical compound FC1=CC([N+](=O)[O-])=CC(F)=C1N1CC(=O)C1 NTIFCJREGXVJAG-UHFFFAOYSA-N 0.000 description 2
- CXWGYHITWCWTFW-UHFFFAOYSA-N 1-(4-amino-2,6-difluorophenyl)-3-(trifluoromethyl)azetidin-3-ol Chemical compound FC1=CC(N)=CC(F)=C1N1CC(O)(C(F)(F)F)C1 CXWGYHITWCWTFW-UHFFFAOYSA-N 0.000 description 2
- HCRRMTGQFHWEKU-UHFFFAOYSA-N 3,5-difluoro-4-(3-fluoroazetidin-1-yl)aniline Chemical compound FC1=CC(N)=CC(F)=C1N1CC(F)C1 HCRRMTGQFHWEKU-UHFFFAOYSA-N 0.000 description 2
- WNARQMJGAKPVET-UHFFFAOYSA-N 4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroaniline Chemical compound FC1=CC(N)=CC(F)=C1N1CC(F)(F)C1 WNARQMJGAKPVET-UHFFFAOYSA-N 0.000 description 2
- JVVKCAVSUAGHAI-UHFFFAOYSA-N 4-(3,3-difluoroazetidin-1-yl)-3-fluoroaniline Chemical compound FC1=CC(N)=CC=C1N1CC(F)(F)C1 JVVKCAVSUAGHAI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000495778 Escherichia faecalis Species 0.000 description 2
- KSRWIQLAVYXQQN-SNVBAGLBSA-N FC=1C=C(C=C(C1N1CC(C1)(C(F)(F)F)O)F)NC[C@H](C(=O)OC)O Chemical compound FC=1C=C(C=C(C1N1CC(C1)(C(F)(F)F)O)F)NC[C@H](C(=O)OC)O KSRWIQLAVYXQQN-SNVBAGLBSA-N 0.000 description 2
- WQNSYNUCKKGLLS-LEHRNKBSSA-N FC=1C=C(C=CC1C1CC(C1)O[Si](C)(C)C(C)(C)C)NC[C@H](C(=O)OC)O Chemical compound FC=1C=C(C=CC1C1CC(C1)O[Si](C)(C)C(C)(C)C)NC[C@H](C(=O)OC)O WQNSYNUCKKGLLS-LEHRNKBSSA-N 0.000 description 2
- GYVSTVXOAVHHJX-UHFFFAOYSA-N FC=1C=C(N)C=CC1C1CC(C1)O[Si](C)(C)C(C)(C)C Chemical compound FC=1C=C(N)C=CC1C1CC(C1)O[Si](C)(C)C(C)(C)C GYVSTVXOAVHHJX-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical group O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical class Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000022760 infectious otitis media Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- HAEBUPMZSKQHRT-LLVKDONJSA-N methyl (2r)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)anilino]-2-hydroxypropanoate Chemical compound FC1=CC(NC[C@@H](O)C(=O)OC)=CC(F)=C1N1CC(F)C1 HAEBUPMZSKQHRT-LLVKDONJSA-N 0.000 description 2
- SYUMUMCWHFBOGG-SNVBAGLBSA-N methyl (2r)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroanilino]-2-hydroxypropanoate Chemical compound FC1=CC(NC[C@@H](O)C(=O)OC)=CC(F)=C1N1CC(F)(F)C1 SYUMUMCWHFBOGG-SNVBAGLBSA-N 0.000 description 2
- HHHFRFOJAMRPEY-LLVKDONJSA-N methyl (2r)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluoroanilino]-2-hydroxypropanoate Chemical compound FC1=CC(NC[C@@H](O)C(=O)OC)=CC=C1N1CC(F)(F)C1 HHHFRFOJAMRPEY-LLVKDONJSA-N 0.000 description 2
- DIKPWYJDXRDOEN-QDPIBXHXSA-N methyl (5r)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate Chemical compound O=C1O[C@@H](C(=O)OC)CN1C(C=C1F)=CC=C1C1CC(O)C1 DIKPWYJDXRDOEN-QDPIBXHXSA-N 0.000 description 2
- WSPSXAMRPDVVLB-PFMWSLTASA-N methyl (5r)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate Chemical compound C1C(OC)CC1C1=CC=C(N2C(O[C@H](C2)C(=O)OC)=O)C=C1F WSPSXAMRPDVVLB-PFMWSLTASA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- GGTBVKOJUABMSG-UHFFFAOYSA-N (1-benzylazetidin-3-yl)oxy-trimethylsilane Chemical compound C1C(O[Si](C)(C)C)CN1CC1=CC=CC=C1 GGTBVKOJUABMSG-UHFFFAOYSA-N 0.000 description 1
- LZVNSRPSJXCADH-UHFFFAOYSA-N 1-(2,6-difluoro-4-nitrophenyl)-3,3-difluoroazetidine Chemical compound FC1=CC([N+](=O)[O-])=CC(F)=C1N1CC(F)(F)C1 LZVNSRPSJXCADH-UHFFFAOYSA-N 0.000 description 1
- KWDFWMLBBZAERA-UHFFFAOYSA-N 1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)azetidin-3-ol Chemical compound C1C(O)(C(F)(F)F)CN1C1=C(F)C=C([N+]([O-])=O)C=C1F KWDFWMLBBZAERA-UHFFFAOYSA-N 0.000 description 1
- WYVOEVCNJSXLFK-UHFFFAOYSA-N 1-(2,6-difluoro-4-nitrophenyl)-3-fluoroazetidine Chemical compound FC1=CC([N+](=O)[O-])=CC(F)=C1N1CC(F)C1 WYVOEVCNJSXLFK-UHFFFAOYSA-N 0.000 description 1
- XMIVQOXTPITAMR-UHFFFAOYSA-N 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-ol Chemical compound C1C(O)CN1C1=C(F)C=C([N+]([O-])=O)C=C1F XMIVQOXTPITAMR-UHFFFAOYSA-N 0.000 description 1
- ZQQSYPZAPHRXRY-UHFFFAOYSA-N 1-hydroxyazetidine Chemical group ON1CCC1 ZQQSYPZAPHRXRY-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- OZMCIZDEFIDDJW-UHFFFAOYSA-N 3,3-dichlorocyclobutan-1-one Chemical compound ClC1(CC(C1)=O)Cl OZMCIZDEFIDDJW-UHFFFAOYSA-N 0.000 description 1
- JYISOWSIMSVXSV-UHFFFAOYSA-N 3,3-difluoro-1-(2-fluoro-4-nitrophenyl)azetidine Chemical compound FC1=CC([N+](=O)[O-])=CC=C1N1CC(F)(F)C1 JYISOWSIMSVXSV-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910007565 Zn—Cu Inorganic materials 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000002895 cranial sinus Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001930 cyclobutanes Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ORPJQSFBLBHKPN-UHFFFAOYSA-N dichloromethane;methylsulfinylmethane Chemical compound ClCCl.CS(C)=O ORPJQSFBLBHKPN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- LSGWSXRILNPXKJ-SCSAIBSYSA-N ethyl (2r)-oxirane-2-carboxylate Chemical compound CCOC(=O)[C@H]1CO1 LSGWSXRILNPXKJ-SCSAIBSYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- AZFQCTBZOPUVOW-UHFFFAOYSA-N methyl(triphenyl)phosphanium Chemical class C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 AZFQCTBZOPUVOW-UHFFFAOYSA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof as antibacterial agents.
Description
OXAZOLIDINONE CARBOXAMIDES CONTAIlVING AZETIDINE AND
CYCLOBUTANE AS ANTIBACTERIAL AGENTS
FIELD OF INVENTION
The present invention relates to novel oxazolidinones carboxamide derivatives bearing azetidine and cyclobutane rings, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. These compounds have potent activities against gram-positive and/or gram-negative bacteria.
BACKGROUND OF THE INVENTION
Antibacterial resistance is a global clinical and public health problem that has emerged with alarming rapidity in recent years and undoubtedly will increase in the near future. Resistance is a problem in the community as well as in health care settings, where transmission of bacteria is greatly amplified. Because multiple drug resistance is a growing problem, physicians are now confronted with infections for which there is no effective therapy. As result, structurally novel antibacterials with a new mode of action have become increasingly important in the treatment of bacterial infections.
Among newer antibacterial agents, oxazolidinone compounds are the most recent synthetic class of antimicrobials. This invention provides azetidine and cyclobutane derivatives of oxazolidinones as an inhibitors of bacterial protein synthesis for the treatment of serious infections caused by a number of human and veterinary pathogens, including multiple resistant strains of bacteria.
INFORMATION DISCLOSURE
DE10129725, JP11322729, US4705799, WO9613502, WO9710223, W09854161, W09912914, WO200027830, WO200032599, W0200232857, W0200206278, WO2003072553, WO2003008389, WO2003007870, WO2003006440, WO2004014392 disclose oxazolidinone compounds useful as antibacterial agents.
The present invention provides a compound of formula I
vi_Y2 Ri ~Z~/ N 0 N-ss R2 Y3=Y4 w I
or a pharmaceutically acceptable salt thereof wherein:
WisOorS;
Yl, Y2, Y3, Y4 are independently CH or CF;
Z is CH or N;
Rl and R2 are independently (a) -H, (b) halo, (c) -CN
(d) -C(=W)NR3Ra.
(e) -(C=0)C1_6alkyl (f) -(C=O)C3_$cycloalkyl (g) -COOH
(h) -C1_6alkyl, (i) -WC1_6alkyl, (j) -C3_$cycloalkyl, (k) -OC3.8cycloalkyl, or (1) R' and R2 taken together form =0, =N-OH, =N-OC1_~alkyl, =CH-CN;
R3 is -H, -C1_6alkyl, or -OC1.6alkyl;
at each occurrence, C1_6alkyl, or C3_8cycloalkyl is optionally substituted with CF3, 1-3 halo, OH, OC1_4alkyl, CN, N3, O(C=O)C1_4 alkyl, C3_6cycloalkyl, NH2, NHC(=O)Ci_4 alkyl, or C(=O)C1_4 alkyl; and nis0,1,or2.
In another aspect, the present invention also provides:
a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I, a method for treating gram-positive microbial infections in a mammal by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating gram-positive or gram-negative microbial infections.
The invention may also provide novel intermediates and novel processes that are useful for preparing compounds of formula I.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C; -j indicates a moiety of the integer "i" to the integer "j"
carbon atoms, inclusive.
Thus, for example, C1_6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
The term alkyl, or alkenyl, etc. refer to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.
CYCLOBUTANE AS ANTIBACTERIAL AGENTS
FIELD OF INVENTION
The present invention relates to novel oxazolidinones carboxamide derivatives bearing azetidine and cyclobutane rings, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. These compounds have potent activities against gram-positive and/or gram-negative bacteria.
BACKGROUND OF THE INVENTION
Antibacterial resistance is a global clinical and public health problem that has emerged with alarming rapidity in recent years and undoubtedly will increase in the near future. Resistance is a problem in the community as well as in health care settings, where transmission of bacteria is greatly amplified. Because multiple drug resistance is a growing problem, physicians are now confronted with infections for which there is no effective therapy. As result, structurally novel antibacterials with a new mode of action have become increasingly important in the treatment of bacterial infections.
Among newer antibacterial agents, oxazolidinone compounds are the most recent synthetic class of antimicrobials. This invention provides azetidine and cyclobutane derivatives of oxazolidinones as an inhibitors of bacterial protein synthesis for the treatment of serious infections caused by a number of human and veterinary pathogens, including multiple resistant strains of bacteria.
INFORMATION DISCLOSURE
DE10129725, JP11322729, US4705799, WO9613502, WO9710223, W09854161, W09912914, WO200027830, WO200032599, W0200232857, W0200206278, WO2003072553, WO2003008389, WO2003007870, WO2003006440, WO2004014392 disclose oxazolidinone compounds useful as antibacterial agents.
The present invention provides a compound of formula I
vi_Y2 Ri ~Z~/ N 0 N-ss R2 Y3=Y4 w I
or a pharmaceutically acceptable salt thereof wherein:
WisOorS;
Yl, Y2, Y3, Y4 are independently CH or CF;
Z is CH or N;
Rl and R2 are independently (a) -H, (b) halo, (c) -CN
(d) -C(=W)NR3Ra.
(e) -(C=0)C1_6alkyl (f) -(C=O)C3_$cycloalkyl (g) -COOH
(h) -C1_6alkyl, (i) -WC1_6alkyl, (j) -C3_$cycloalkyl, (k) -OC3.8cycloalkyl, or (1) R' and R2 taken together form =0, =N-OH, =N-OC1_~alkyl, =CH-CN;
R3 is -H, -C1_6alkyl, or -OC1.6alkyl;
at each occurrence, C1_6alkyl, or C3_8cycloalkyl is optionally substituted with CF3, 1-3 halo, OH, OC1_4alkyl, CN, N3, O(C=O)C1_4 alkyl, C3_6cycloalkyl, NH2, NHC(=O)Ci_4 alkyl, or C(=O)C1_4 alkyl; and nis0,1,or2.
In another aspect, the present invention also provides:
a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I, a method for treating gram-positive microbial infections in a mammal by administering to the subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating gram-positive or gram-negative microbial infections.
The invention may also provide novel intermediates and novel processes that are useful for preparing compounds of formula I.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C; -j indicates a moiety of the integer "i" to the integer "j"
carbon atoms, inclusive.
Thus, for example, C1_6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
The term alkyl, or alkenyl, etc. refer to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.
The term "C3_8cycloalkyl" or "C3_6cycloalkyl" refers to a cyclic saturated monovalent hydrocarbon group of three to eight or three to six carbon atoms, e.g., cyclopropyl, cyclohexyl, and the like.
The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
The term "a pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
The term "pharmaceutically acceptable carrier" means a carrier that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier that is acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable carrier" as used in the specification and claims includes both one and more than one such carrier.
The term "mammal" refers to human or warm-blooded animals including livestock and companion animals.
The term "optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers".
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms.
Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antiviral activity using the standard tests described herein, or using other similar tests which are well known in the art.
The term "treating" or "treatment" of a disease includes: (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
The term "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
The term "leaving group" has the meaning conventionally associated with it in synthetic organic chemistry i.e., an atom or group capable of being displaced by a nucleophile and includes halogen, alkylsulfonyloxy, ester, or amino such as chloro, bromo, iodo, mesyloxy, tosyloxy, trifluorosulfonyloxy, methoxy, N,O-dimethylhydroxyl-amino, and the like.
The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system.
Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for an hour or hours and "rt" for room temperature).
Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
Specifically, alkyl is methyl or ethyl.
Specifically, halo is fluoro (F).
Specifically, R' and R2 are independently H, F, OH, OC1_2alkyl, Cl_Zalkyl, or CF3.
Specifically, Y2 and Y4 are CH; and Yland Y3 are independently CH or CF.
Specifically, R3 is H or CH3.
Examples of the present invention are (1) (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (2) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (3) (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3oxazolidine-5-carboxamide, (4) (5R)-3-{ 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl }-2-oxo-1,3-oxazolidine-5-carboxamide, (5) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (6) (5R)-N-methyl-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (7) (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (8) (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (9) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, or (10) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-1,3-oxazolidine-5-carboxamide.
Compounds of this invention can be prepared in accordance with one or more of the Schemes discussed below. All of the starting materials are either commercially available or can be prepared by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the Schemes are as defined below, or as in the summary of the invention or claims.
Scheme I
Ri Y1 Ri Yl H OH
!~Z--~/ Z~/ N~O RY33-NH 2 R2 Ya-Rs~Z ~N O ' Ri~Z ' 1 O H
R2 Ya ~ R2 Y3 ~N'R3 Scheme I describes the synthesis of analogs bearing carboxamide substitution at C-5 of the oxazolidinone. First, the aniline intermediate 1 is reacted with an alkyl (2R)-epoxypropanoate and a Lewis acid such as lithium triflate as described in US
Patent Application Publication No. US 2004/0044052.
In step 2, the amino alcohol (2) is cyclized to give the aryl oxazolidinones 3 using methods known to one skilled in the art. For instance, treatment of intennediate 2 with 1,1'-carbonyldiimidazole in a solvent such as acetonitrile or tetrahydrofuran at an appropriate temperature, typically in a range of 20 C to 80 C provides the oxazolidinone 3.
Alternatively, reaction of 2 with phosgene in a solvent such as toluene or methylene chloride, or mixtures thereof, in the presence of a base such as triethylamine at an appropriate temperature, typically in a range from -10 C to 25 C, affords the oxazolidinone 3. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Subsequent treatment of oxazolidinone ester 3 with ammonia or optionally with substituted amines (RNH2) in a suitable solvent such as methanol or acetonitrile affords amides 4 (R = H or optionally substituted alkyl). Similarly, treatment of ester 3 with 0-alkylhydoxylamines or hydrazines gives the hydroxamate (R = 0-alkyl) or the hydrazide (R =
NH2) respectively. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Scheme II
F
HO-CNH + F /~ NO2 -~ HO--~N O_NO2 F F
F F
R2N / ~ N02 R ~N / ~ NH2 F F
Intermediates bearing azetidine substitution are conveniently prepared by the nucleophilic aromatic substitution reaction of 3-hydroxyazetidine with fluorinated nitro aromatic compounds. Such reactions are well known those skilled in the art and review articles describing these reactions are available (see Zoltewicz in Top. Curr.
Chem. 1975, vol.
59, pp. 33-64). These transformations are generally performed at 40 C to 90 C
using polar aprotic solvents such as acetonitrile or dimethylformamide and in the presence of acid-scavenging bases such as triethylamine or N,N-diisopropylethylamine. The 3-hydroxyazetidine 1 is prepared by hydrogenolysis (for example with Pd/C in methanol) of 1-benzyl-3-trimethylsilyloxyazetidine (prepared as described by Higgins, R. H.
J. Heterocyclic Chem. 1987, 24, 1489).. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 2 of Scheme 4 represents one or more steps required for the protection, oxidation, or otherwise conversion of the hydroxyazetidine ring to a more highly functionalized state. A person of ordinary skill in organic chemistry will be well acquainted with the various reactions that will be required for this functionalization.
This may involve, for example, protection as a silyl ether, fluorination, oxidation to the azetidinone, olefination of the azetidione thus obtained, reaction of the azetidinone thus obtained with nucleophiles, or activation of the hydroxy group and substitution with nucleophiles. The products may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Finally, step 3 involves reduction of the nitro group to provide the aniline intermediate 5. This reduction is generally accomplished by reacting the nitro intermediate 4 with iron metal. The reaction is carried out at temperatures between 60 C and 90 C in mixtures of water and alcohol (methanol, ethanol, etc.) as solvent, and in the presence of ammonium chloride to buffer the reaction mixture. Optionally, reductions of this type are conducted by reaction with other metals such as tin or zinc or by hydrogenation under palladium or platinum catalysis (see Rylander Hydrogenation Methods; Academic Press:
New York, 1985, pp. 104-116).. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Scheme III
O~ }Br --' Oo s~NHCbz-- --~ 3 j-NHCbz Y3 Y ~~ Y -/
-> 0==<>-0 NHCbz ~NHCbV
Scheme III describes the synthesis of intermediates bearing a cyclobutane ring. The intermediate 2 can be prepared in a single step involving the transition metal catalyzed reaction of a 4-bromo benzaldehyde starting material (1) with an alkyl carbamate, for example benzyl carbamate. Reactions of this type are well known to those skilled in the art (see for example Buchwald et.al. J. Am. Chem. Soc. 2002, 124, 7421-7428) and are typically carried out with palladium or copper catalysts and employing ligands such as BINAP or related phosphine or arsine ligands. The reaction is favorably carried out in solvents such as toluene or benzene and at temperatures of about 50 C up to 110 C. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 2 of Scheme 5 involves the conversion of benzaldehyde intermediate 2 to the styrene 3. Olefination of 2 is accomplished under conditions well-known to those of ordinary skill in organic chemistry, for example by reaction of the aldehyde with a phophorus ylide (generated by the reaction of a methyltriphenylphosphonium salt with a base such as sodium hydride or potassium bis(trimethylsilyl)amide). The reaction is typically carried out in solvents such as THF or DMF and at temperatures of about -50 C up to 25 C.
The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
In step 3 of Scheme 5, the cyclobutanone ring is formed by the reaction of the styrene intermediate 3 with dichlorocarbene followed by a dechlorination step to provide 4.
The generation and [2-1-2] cycloaddition of dichlorocarbene with olefins is well known and review articles describing these reactions are available (for example, see Brady, W. T.
Tetrahedron 1981, 17, 2949-2966). The dichlorocyclobutanone intermediate formed in the cycloaddition reaction is then dechlorinated by reaction with reducing metals (for example with Zn-Cu couple) to form the desired cyclobutanone intermediate. Such reduction reactions are well known and are discussed in review articles, including that referenced above. The products of these reactions may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 4 of Scheme 5 represents one or more steps required for the protection, reduction, or otherwise conversion of the azetidinone ring to a more highly functionalized state. This may involve, for example, reduction, protection of the alcohol thus formed as a silyl ether, fluorination, olefination reactions, oxime formation, or reaction with nucleophiles.
The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Medical and Veterinary Uses The compounds of the present invention may be used for the treatment of infectious, Gram-positive bacterial infections caused by a variety of bacterial organisms, including those that require long-term therapy (>28 days).
Examples of the bacterial organisms include gram-positive bacteria such as multiple resistant staphylococci, for example S. aureus and S. epidermidis; multiple resistant streptococci, for example S. pneumoniae and S. pyogenes; and multiple resistant Enterococci, for example E. faecalis; gram negative aerobic bacteria such as Haemophilus, for example H.
influenzae and Moraxella, for example M. catarrhalis; as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacteria, for example M. tuberculosis; and/or Mycobacterium avium. Other examples include Escherichia, for example E. coli. intercellular microbes, for example Chlamydia and Rickettsiae.
Examples of infections that may be treated with the compounds of the present invention include central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, bums, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients. Specifically, infectious diseases that may be treated with the compounds of the present invention are gram-positive infections such as osteomyelitis, endocarditis and diabetic foot.
Antibacterial Activities The in vitro antibacterial activity of the compounds of the present invention may be assessed by following procedures recommended in (1) National Committee for Clinical Laboratory Standards (Jan. 2003), Metlaods for dilution antimicrobial tests for bacteria that grow aerobically, Approved Standard (6"' ed), M7-A6, NCCLS, Wayne, PA; (2) National Committee for Clinical Laboratory Standards (Mar. 2001), Methods for antimicrobial susceptibility testing of anaerobic bacteria, Approved Standard (5'" ed), M11-A4, NCCLS, Wayne, PA; (3) National Committee for Clinical Laboratory Standards (Jan.2003), MIC
testing supplemental tables, M100-S13 (for use with M7-A6), NCCLS, Wayne, PA;
and (4) Murray PR, Baron EJ, Jorgensen JH, et al. Manual of Clinical Microbiology (8'h ed) Washington, DC: American Society for Microbiology Press, 2003. The antibacterial activity can be presented in the form of MIC value. The MIC value is the lowest concentration of drug which prevented macroscopically visible growth under the conditions of the test. The antibacterial activities are shown in Table 1.
Table I
Results of in vitro antibacterial activity MIC40 ( g/mL) Example No. S. aureus S. pneumoniae E.faecalis Pharmaceutical Salts The compound of formula I may be used in its native form or as a salt. In cases where forming a stable nontoxic acid or base salt is desired, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts of the present invention include inorganic salts such as hydrochloride, hydrobromide, sulfate, nitrate, bicarbonate, carbonate salts, and organic salts such as tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, etoglutarate, and glycerophosphate.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example, reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Routes of Administration In therapeutic use for treating, or combating, bacterial infections in a mammal (i.e.
human and animals) an oxazolidinone prodrug of the present invention or its pharmaceutical compositions can be administered orally, parenterally, topically, rectally, transmucosally, or intestinally.
Parenteral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Examples of parenteral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intranasal, intravetricular injections or infusions techniques.
Topical administrations include the treatment of infectious areas or organs readily accessibly by local application, such as, for example, eyes, ears including external and middle ear infections, vaginal, open wound, skins including the surface skin and the underneath dermal structures, or other lower intestinal tract. It also includes transdermal delivery to generate a systemic effect.
The rectal administration includes the form of suppositories.
The transmucosal administration includes nasal aerosol or inhalation applications.
The preferred routes of administration are oral and parenteral.
Composition/Formulation Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, solutions, emulsions, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. A carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Examples of such carriers or excipients include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, sucrose, pectin, dextrin, mannitol, sorbitol, starches, gelatin, cellulosic materials, low melting wax, cocoa butter or powder, polymers such as polyethylene glycols and other pharmaceutical acceptable materials.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, liquid polyethylene glycols, cremophor, capmul, medium or long chain mono-, di- or triglycerides.
Stabilizers may be added in these formulations, also.
Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
The compounds may also be formulated for parenteral administration, e.g., by injections, bolus injection or continuous infusion. Formulations for parenteral administration may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.
The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
The term "a pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
The term "pharmaceutically acceptable carrier" means a carrier that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier that is acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable carrier" as used in the specification and claims includes both one and more than one such carrier.
The term "mammal" refers to human or warm-blooded animals including livestock and companion animals.
The term "optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers".
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms.
Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antiviral activity using the standard tests described herein, or using other similar tests which are well known in the art.
The term "treating" or "treatment" of a disease includes: (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
The term "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
The term "leaving group" has the meaning conventionally associated with it in synthetic organic chemistry i.e., an atom or group capable of being displaced by a nucleophile and includes halogen, alkylsulfonyloxy, ester, or amino such as chloro, bromo, iodo, mesyloxy, tosyloxy, trifluorosulfonyloxy, methoxy, N,O-dimethylhydroxyl-amino, and the like.
The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system.
Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for an hour or hours and "rt" for room temperature).
Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
Specifically, alkyl is methyl or ethyl.
Specifically, halo is fluoro (F).
Specifically, R' and R2 are independently H, F, OH, OC1_2alkyl, Cl_Zalkyl, or CF3.
Specifically, Y2 and Y4 are CH; and Yland Y3 are independently CH or CF.
Specifically, R3 is H or CH3.
Examples of the present invention are (1) (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (2) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (3) (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3oxazolidine-5-carboxamide, (4) (5R)-3-{ 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl }-2-oxo-1,3-oxazolidine-5-carboxamide, (5) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (6) (5R)-N-methyl-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (7) (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (8) (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (9) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, or (10) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-1,3-oxazolidine-5-carboxamide.
Compounds of this invention can be prepared in accordance with one or more of the Schemes discussed below. All of the starting materials are either commercially available or can be prepared by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the Schemes are as defined below, or as in the summary of the invention or claims.
Scheme I
Ri Y1 Ri Yl H OH
!~Z--~/ Z~/ N~O RY33-NH 2 R2 Ya-Rs~Z ~N O ' Ri~Z ' 1 O H
R2 Ya ~ R2 Y3 ~N'R3 Scheme I describes the synthesis of analogs bearing carboxamide substitution at C-5 of the oxazolidinone. First, the aniline intermediate 1 is reacted with an alkyl (2R)-epoxypropanoate and a Lewis acid such as lithium triflate as described in US
Patent Application Publication No. US 2004/0044052.
In step 2, the amino alcohol (2) is cyclized to give the aryl oxazolidinones 3 using methods known to one skilled in the art. For instance, treatment of intennediate 2 with 1,1'-carbonyldiimidazole in a solvent such as acetonitrile or tetrahydrofuran at an appropriate temperature, typically in a range of 20 C to 80 C provides the oxazolidinone 3.
Alternatively, reaction of 2 with phosgene in a solvent such as toluene or methylene chloride, or mixtures thereof, in the presence of a base such as triethylamine at an appropriate temperature, typically in a range from -10 C to 25 C, affords the oxazolidinone 3. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Subsequent treatment of oxazolidinone ester 3 with ammonia or optionally with substituted amines (RNH2) in a suitable solvent such as methanol or acetonitrile affords amides 4 (R = H or optionally substituted alkyl). Similarly, treatment of ester 3 with 0-alkylhydoxylamines or hydrazines gives the hydroxamate (R = 0-alkyl) or the hydrazide (R =
NH2) respectively. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Scheme II
F
HO-CNH + F /~ NO2 -~ HO--~N O_NO2 F F
F F
R2N / ~ N02 R ~N / ~ NH2 F F
Intermediates bearing azetidine substitution are conveniently prepared by the nucleophilic aromatic substitution reaction of 3-hydroxyazetidine with fluorinated nitro aromatic compounds. Such reactions are well known those skilled in the art and review articles describing these reactions are available (see Zoltewicz in Top. Curr.
Chem. 1975, vol.
59, pp. 33-64). These transformations are generally performed at 40 C to 90 C
using polar aprotic solvents such as acetonitrile or dimethylformamide and in the presence of acid-scavenging bases such as triethylamine or N,N-diisopropylethylamine. The 3-hydroxyazetidine 1 is prepared by hydrogenolysis (for example with Pd/C in methanol) of 1-benzyl-3-trimethylsilyloxyazetidine (prepared as described by Higgins, R. H.
J. Heterocyclic Chem. 1987, 24, 1489).. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 2 of Scheme 4 represents one or more steps required for the protection, oxidation, or otherwise conversion of the hydroxyazetidine ring to a more highly functionalized state. A person of ordinary skill in organic chemistry will be well acquainted with the various reactions that will be required for this functionalization.
This may involve, for example, protection as a silyl ether, fluorination, oxidation to the azetidinone, olefination of the azetidione thus obtained, reaction of the azetidinone thus obtained with nucleophiles, or activation of the hydroxy group and substitution with nucleophiles. The products may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Finally, step 3 involves reduction of the nitro group to provide the aniline intermediate 5. This reduction is generally accomplished by reacting the nitro intermediate 4 with iron metal. The reaction is carried out at temperatures between 60 C and 90 C in mixtures of water and alcohol (methanol, ethanol, etc.) as solvent, and in the presence of ammonium chloride to buffer the reaction mixture. Optionally, reductions of this type are conducted by reaction with other metals such as tin or zinc or by hydrogenation under palladium or platinum catalysis (see Rylander Hydrogenation Methods; Academic Press:
New York, 1985, pp. 104-116).. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Scheme III
O~ }Br --' Oo s~NHCbz-- --~ 3 j-NHCbz Y3 Y ~~ Y -/
-> 0==<>-0 NHCbz ~NHCbV
Scheme III describes the synthesis of intermediates bearing a cyclobutane ring. The intermediate 2 can be prepared in a single step involving the transition metal catalyzed reaction of a 4-bromo benzaldehyde starting material (1) with an alkyl carbamate, for example benzyl carbamate. Reactions of this type are well known to those skilled in the art (see for example Buchwald et.al. J. Am. Chem. Soc. 2002, 124, 7421-7428) and are typically carried out with palladium or copper catalysts and employing ligands such as BINAP or related phosphine or arsine ligands. The reaction is favorably carried out in solvents such as toluene or benzene and at temperatures of about 50 C up to 110 C. The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 2 of Scheme 5 involves the conversion of benzaldehyde intermediate 2 to the styrene 3. Olefination of 2 is accomplished under conditions well-known to those of ordinary skill in organic chemistry, for example by reaction of the aldehyde with a phophorus ylide (generated by the reaction of a methyltriphenylphosphonium salt with a base such as sodium hydride or potassium bis(trimethylsilyl)amide). The reaction is typically carried out in solvents such as THF or DMF and at temperatures of about -50 C up to 25 C.
The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
In step 3 of Scheme 5, the cyclobutanone ring is formed by the reaction of the styrene intermediate 3 with dichlorocarbene followed by a dechlorination step to provide 4.
The generation and [2-1-2] cycloaddition of dichlorocarbene with olefins is well known and review articles describing these reactions are available (for example, see Brady, W. T.
Tetrahedron 1981, 17, 2949-2966). The dichlorocyclobutanone intermediate formed in the cycloaddition reaction is then dechlorinated by reaction with reducing metals (for example with Zn-Cu couple) to form the desired cyclobutanone intermediate. Such reduction reactions are well known and are discussed in review articles, including that referenced above. The products of these reactions may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Step 4 of Scheme 5 represents one or more steps required for the protection, reduction, or otherwise conversion of the azetidinone ring to a more highly functionalized state. This may involve, for example, reduction, protection of the alcohol thus formed as a silyl ether, fluorination, olefination reactions, oxime formation, or reaction with nucleophiles.
The product may be used as collected or may first be purifed using conventional techniques such as preparative TLC or HPLC, chromatography, precipitation, crystallization and the like.
Medical and Veterinary Uses The compounds of the present invention may be used for the treatment of infectious, Gram-positive bacterial infections caused by a variety of bacterial organisms, including those that require long-term therapy (>28 days).
Examples of the bacterial organisms include gram-positive bacteria such as multiple resistant staphylococci, for example S. aureus and S. epidermidis; multiple resistant streptococci, for example S. pneumoniae and S. pyogenes; and multiple resistant Enterococci, for example E. faecalis; gram negative aerobic bacteria such as Haemophilus, for example H.
influenzae and Moraxella, for example M. catarrhalis; as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacteria, for example M. tuberculosis; and/or Mycobacterium avium. Other examples include Escherichia, for example E. coli. intercellular microbes, for example Chlamydia and Rickettsiae.
Examples of infections that may be treated with the compounds of the present invention include central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, bums, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients. Specifically, infectious diseases that may be treated with the compounds of the present invention are gram-positive infections such as osteomyelitis, endocarditis and diabetic foot.
Antibacterial Activities The in vitro antibacterial activity of the compounds of the present invention may be assessed by following procedures recommended in (1) National Committee for Clinical Laboratory Standards (Jan. 2003), Metlaods for dilution antimicrobial tests for bacteria that grow aerobically, Approved Standard (6"' ed), M7-A6, NCCLS, Wayne, PA; (2) National Committee for Clinical Laboratory Standards (Mar. 2001), Methods for antimicrobial susceptibility testing of anaerobic bacteria, Approved Standard (5'" ed), M11-A4, NCCLS, Wayne, PA; (3) National Committee for Clinical Laboratory Standards (Jan.2003), MIC
testing supplemental tables, M100-S13 (for use with M7-A6), NCCLS, Wayne, PA;
and (4) Murray PR, Baron EJ, Jorgensen JH, et al. Manual of Clinical Microbiology (8'h ed) Washington, DC: American Society for Microbiology Press, 2003. The antibacterial activity can be presented in the form of MIC value. The MIC value is the lowest concentration of drug which prevented macroscopically visible growth under the conditions of the test. The antibacterial activities are shown in Table 1.
Table I
Results of in vitro antibacterial activity MIC40 ( g/mL) Example No. S. aureus S. pneumoniae E.faecalis Pharmaceutical Salts The compound of formula I may be used in its native form or as a salt. In cases where forming a stable nontoxic acid or base salt is desired, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts of the present invention include inorganic salts such as hydrochloride, hydrobromide, sulfate, nitrate, bicarbonate, carbonate salts, and organic salts such as tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, etoglutarate, and glycerophosphate.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example, reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Routes of Administration In therapeutic use for treating, or combating, bacterial infections in a mammal (i.e.
human and animals) an oxazolidinone prodrug of the present invention or its pharmaceutical compositions can be administered orally, parenterally, topically, rectally, transmucosally, or intestinally.
Parenteral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Examples of parenteral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intranasal, intravetricular injections or infusions techniques.
Topical administrations include the treatment of infectious areas or organs readily accessibly by local application, such as, for example, eyes, ears including external and middle ear infections, vaginal, open wound, skins including the surface skin and the underneath dermal structures, or other lower intestinal tract. It also includes transdermal delivery to generate a systemic effect.
The rectal administration includes the form of suppositories.
The transmucosal administration includes nasal aerosol or inhalation applications.
The preferred routes of administration are oral and parenteral.
Composition/Formulation Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulation, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, solutions, emulsions, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. A carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Examples of such carriers or excipients include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, sucrose, pectin, dextrin, mannitol, sorbitol, starches, gelatin, cellulosic materials, low melting wax, cocoa butter or powder, polymers such as polyethylene glycols and other pharmaceutical acceptable materials.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, liquid polyethylene glycols, cremophor, capmul, medium or long chain mono-, di- or triglycerides.
Stabilizers may be added in these formulations, also.
Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
The compounds may also be formulated for parenteral administration, e.g., by injections, bolus injection or continuous infusion. Formulations for parenteral administration may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.
For injection, the compounds of the invention may be formulated in aqueous solution, preferably in physiologically compatible buffers or physiological saline buffer.
Suitable buffering agents include trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine.
Parenteral administrations also include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
For suppository administration, the compounds may also be formulated by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
Such materials include cocoa butter, beeswax and other glycerides.
For administration by inhalation, compounds of the present invention can be conveniently delivered through an aerosol spray in the form of solution, dry powder, or suspensions. The aerosol may use a pressurized pack or a nebulizer and a suitable propellant.
In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler may be formulated containing a power base such as lactose or starch.
For topical applications, the pharmaceutical composition may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion such as suspensions, emulsion, or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, ceteary alcohol, 2-octyldodecanol, benzyl alcohol and water.
Suitable buffering agents include trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine.
Parenteral administrations also include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
For suppository administration, the compounds may also be formulated by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
Such materials include cocoa butter, beeswax and other glycerides.
For administration by inhalation, compounds of the present invention can be conveniently delivered through an aerosol spray in the form of solution, dry powder, or suspensions. The aerosol may use a pressurized pack or a nebulizer and a suitable propellant.
In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler may be formulated containing a power base such as lactose or starch.
For topical applications, the pharmaceutical composition may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion such as suspensions, emulsion, or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, ceteary alcohol, 2-octyldodecanol, benzyl alcohol and water.
For ophthalmic and otitis uses, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as a benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be in the form of implants. A compound of this invention may be formulated for this route of administration with suitable polymers, hydrophobic materials, or as a sparing soluble derivative such as, without limitation, a sparingly soluble salt.
Additionally, the compounds may be delivered using a sustained-release system.
Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for 24 hours or for up to several days.
DosaLye Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, i.e., the treatment or prevent of infectious diseases.
More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
The quantity of active component, that is the compound of this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the manner of administration, the potency of the particular compound and the desired concentration. Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
Generally, a therapeutically effective amount of dosage of active component will be in the range of about 0.1 to about 400 mg/kg of body weight/day, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of each subject and the severity of the bacterial infection being treated. In average, the effective amount of active component is about 200 mg to 800 mg and preferable 600 mg per day.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration.
On the other hand, the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures know in the art may be used to determine the desired dosage amount.
Oral Efficacy EXAMPLES
In the discussion above and in the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.
bm = broad multiplet bd = broad doublet bs = broad singlet bt = broad triplet br = broad signal CDI = 1,1 (a-carbodiimidazole d = doublet dd = doublet of doublets dq = doublet of quartets dt = doublet of triplets dm = doublet of multiplets DMF = dimethylformamide DMAP = dimethylaminopyridine DIEA = diisopropylethylamine DMSO = dimethyl sulfoxide eq. = equivalents g = grams h = hours HPLC = high pressure liquid chromatography HATU = N-[(dimethylamino)-IH-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate N-oxide LG = leaving group m = multiplet M = molar M Io = mole percent max = maximum meq = milliequivalent mg = milligram mL = milliliter mm - millimeter mmol = millimol q = quartet s = singlet t or tr = triplet TBS - tributylsilyl TFA - trifluoroacetic acid THF = tetrahydrofuran TLC - thin layer chromatography p-TLC - preparative thin layer chromatography L - microliter N - normality MeOH - methanol DCM - dichloromethane HC1 - hydrochloric acid ACN - acetonitrile MS = mass spectrometry rt = room temperature EtOAc - ethyl acetate EtO - ethoxy Ac - acetate NMP = 1-methyl-2-pyrrolidinone L = microliter J = coupling constant NMR - Nuclear magnetic resonance MHz - megahertz Hz = hertz m/z = mass to charge ratio min = minutes Boc - tert-butoxycarbonyl CBZ = benzyloxycarbonyl DCC = 1,3-dicyclohexylcarbodiimide PyBop - benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate Example 1 Preparation of (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide F
yNH2 F
O
1,1'-Carbonyldiimidazole (0.163 g, 0.98 mmol) is added to a solution of methyl (2R)-3-{[3,5-difluoro-4-(3-fluoroazetidin-l-yl)phenyl]amino}-2-hydroxypropanoate (0.150 g, 0.49 mmol) in acetonitrile (8 mL) and the solution heated to 50 C for three days.
After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide methyl (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.160 g, 0.49 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 316 'H NMR (300 MHz, CD3CN): 3.96 (dd, J = 9, 6 Hz, 1H), 4.18 (m, 3H), 4.42 (m, 2H), 4.93 (dd, J = 10, 6 Hz, 1H), 5.22- 5.42 (dm, J = 58 Hz, 1H), 6.17 (br s, 1H), 6.70 (br s, 1H), 7.12 (dd, J = 10, 2 Hz, 2H) Intermediates for the synthesis of example 1 are prepared as follows.
I. Preparation of methyl (2R)-3-{[3,5-difluoro-4-(3-fluoroazetidin-l-yl)phenyl]amino}-2-hydroxypropanoate A solution of 1-(2,6-difluoro-4-nitrophenyl)-3-fluoroazetidine (0.36 g, 1.5 mmol) in 2 mL of methanol containing 10% Pd/C (0.04 g) is stirred under an atmosphere of hydrogen.
After 18 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2,6-difluorophenyl)-3-fluoroazetidine which is used directly in the next step.
A solution of 1-(4-amino-2,6-difluorophenyl)-3-fluoroazetidine (1.5 mmol) in acetonitrile (5 mL) is treated with (R)-methyl glycidate (0.18 g, 1.8 mmol) and lithium triflate (0.28 g, 1.8 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.04 (br s, 1H), 3.35-3.48 (m, 2H), 3.81 (s, 3H), 3.91 (br s, IH), 4.06-4.17 (m, 2H), 4.31-4.50 (m, 3H), 5.19-5.39 (dm, J= 58 Hz, 1H), 6.16 (dd, J=
10, 2 Hz, 2H) Example 2 Preparation of (5R)-3-[4-(3,3-difluoroazetidin-l-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide >C3YNH2 O
In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be in the form of implants. A compound of this invention may be formulated for this route of administration with suitable polymers, hydrophobic materials, or as a sparing soluble derivative such as, without limitation, a sparingly soluble salt.
Additionally, the compounds may be delivered using a sustained-release system.
Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for 24 hours or for up to several days.
DosaLye Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, i.e., the treatment or prevent of infectious diseases.
More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
The quantity of active component, that is the compound of this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the manner of administration, the potency of the particular compound and the desired concentration. Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
Generally, a therapeutically effective amount of dosage of active component will be in the range of about 0.1 to about 400 mg/kg of body weight/day, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of each subject and the severity of the bacterial infection being treated. In average, the effective amount of active component is about 200 mg to 800 mg and preferable 600 mg per day.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration.
On the other hand, the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures know in the art may be used to determine the desired dosage amount.
Oral Efficacy EXAMPLES
In the discussion above and in the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.
bm = broad multiplet bd = broad doublet bs = broad singlet bt = broad triplet br = broad signal CDI = 1,1 (a-carbodiimidazole d = doublet dd = doublet of doublets dq = doublet of quartets dt = doublet of triplets dm = doublet of multiplets DMF = dimethylformamide DMAP = dimethylaminopyridine DIEA = diisopropylethylamine DMSO = dimethyl sulfoxide eq. = equivalents g = grams h = hours HPLC = high pressure liquid chromatography HATU = N-[(dimethylamino)-IH-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate N-oxide LG = leaving group m = multiplet M = molar M Io = mole percent max = maximum meq = milliequivalent mg = milligram mL = milliliter mm - millimeter mmol = millimol q = quartet s = singlet t or tr = triplet TBS - tributylsilyl TFA - trifluoroacetic acid THF = tetrahydrofuran TLC - thin layer chromatography p-TLC - preparative thin layer chromatography L - microliter N - normality MeOH - methanol DCM - dichloromethane HC1 - hydrochloric acid ACN - acetonitrile MS = mass spectrometry rt = room temperature EtOAc - ethyl acetate EtO - ethoxy Ac - acetate NMP = 1-methyl-2-pyrrolidinone L = microliter J = coupling constant NMR - Nuclear magnetic resonance MHz - megahertz Hz = hertz m/z = mass to charge ratio min = minutes Boc - tert-butoxycarbonyl CBZ = benzyloxycarbonyl DCC = 1,3-dicyclohexylcarbodiimide PyBop - benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate Example 1 Preparation of (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide F
yNH2 F
O
1,1'-Carbonyldiimidazole (0.163 g, 0.98 mmol) is added to a solution of methyl (2R)-3-{[3,5-difluoro-4-(3-fluoroazetidin-l-yl)phenyl]amino}-2-hydroxypropanoate (0.150 g, 0.49 mmol) in acetonitrile (8 mL) and the solution heated to 50 C for three days.
After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide methyl (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.160 g, 0.49 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 316 'H NMR (300 MHz, CD3CN): 3.96 (dd, J = 9, 6 Hz, 1H), 4.18 (m, 3H), 4.42 (m, 2H), 4.93 (dd, J = 10, 6 Hz, 1H), 5.22- 5.42 (dm, J = 58 Hz, 1H), 6.17 (br s, 1H), 6.70 (br s, 1H), 7.12 (dd, J = 10, 2 Hz, 2H) Intermediates for the synthesis of example 1 are prepared as follows.
I. Preparation of methyl (2R)-3-{[3,5-difluoro-4-(3-fluoroazetidin-l-yl)phenyl]amino}-2-hydroxypropanoate A solution of 1-(2,6-difluoro-4-nitrophenyl)-3-fluoroazetidine (0.36 g, 1.5 mmol) in 2 mL of methanol containing 10% Pd/C (0.04 g) is stirred under an atmosphere of hydrogen.
After 18 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2,6-difluorophenyl)-3-fluoroazetidine which is used directly in the next step.
A solution of 1-(4-amino-2,6-difluorophenyl)-3-fluoroazetidine (1.5 mmol) in acetonitrile (5 mL) is treated with (R)-methyl glycidate (0.18 g, 1.8 mmol) and lithium triflate (0.28 g, 1.8 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.04 (br s, 1H), 3.35-3.48 (m, 2H), 3.81 (s, 3H), 3.91 (br s, IH), 4.06-4.17 (m, 2H), 4.31-4.50 (m, 3H), 5.19-5.39 (dm, J= 58 Hz, 1H), 6.16 (dd, J=
10, 2 Hz, 2H) Example 2 Preparation of (5R)-3-[4-(3,3-difluoroazetidin-l-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide >C3YNH2 O
1,1'-Carbonyldiimidazole (0.155 g, 0.93 mmol) is added to a solution of methyl (2R)-3-{ [4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]amino}-2-hydroxypropanoate (0.10 g, 0.31 mmol) in acetonitrile (4.0 mL) and the solution heated to 50 C for three days. After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.107 g, 0.31 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]} = 334 iH NMR (300 MHz, CD3CN): 3.96 (m, 1H), 4.18 (m, 1H), 4.40-4.52 (m, 4H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.16 (br s, 1H), 6.70 (br s, 1H), 7.17 (dd, J= 10, 2 Hz, 2H) Intermediates for the synthesis of example 2 are prepared as follows.
1. Preparation of methyl (2R)-3-{ [4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl] amino } -2-hydroxypropanoate F \ / NH OMe A solution of 1-(2,6-difluoro-4-nitrophenyl)-3,3-difluoroazetidine (0.25 g, 1.0 mmol) in 2 mL of methanol containing 10% Pd/C (0.050 g) is stirred under an atmosphere of hydrogen. After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroaniline which is used directly in the next step.
A solution of 4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroaniline (1.0 mmol) in acetonitrile (4 mL) is treated with (R)-methyl glycidate (0.185 g, 1.2 mmol) and lithium triflate (0.236 g, 1.5 mmol), heated to 70 C for 3 hours and then cooled and concentrated.
The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.17 (br s, 1H), 3.30-3.45 (m, 2H), 3.81 (s, 311), 3.91 (br s, 1 H), 4.39 (m, 5 H), 6.16 (dd, J = 10, 2 Hz, 2H) Example 3 Preparation of (5R)-3-[4-(3-methoxyazetidin-l-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide P--<~ NH2 n-Butyllithium solution (2.1 mL of a 1.6 M hexanes solution, 3.32 mmol) is added to a cooled (-78 C) solution of benzy13,5-difluoro-4-(3-methoxyazetidin-1-yl)phenylcarbamate (0.77 g, 2.21 mmol) in THF (11 mL). After 10 minutes, ethyl (2R)-2,3-epoxypropanoate (0.77 g, 6.63 mmol) is added and the solution allowed to warm to room temperature and stirred for 18 h. Saturated aqueous ammonium chloride is added to the reaction mixture and extracted with dichloromethane. The aqueous phase is acidified to pH 1 with 1N
HCl and extracted with dichloromethane twice. The combined organic phases are then dried (MgSO4), filtered and concentrated to provide crude (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid that is used directly in the next reaction.
(Trimethylsilyl)diazomethane solution (0.24 mL of a 2M diethylether solution, 0.48 mmol) is added to a solution of (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid (0.24 mmol) in MeOH (0.5 mL). After stirring at room temperature for 2 hours, the reaction mixture is concentrated and treated with methanolic ammonia (1.0 mL of a 2.0 M solution, 2.0 mmol). After 24 hours, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 328 'H NMR (300 MHz, d6-DMSO): 3.20 (s, 3H), 3.84-3.95 (m, 3H), 4.14-4.27 (m, 4H), 4.98 (m, 1H), 7.22 (dd, J = 9, 2 Hz, 2H), 7.60 (br s, 1H), 7.83 (br s, 1H) Example 4 Preparation of (5R)-3-{3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl } -2-oxo-1,3-oxazolidine-5-carboxamide F
F
1,1'-Carbonyldiimidazole (0.018 g, 0.108 mmol) is added to a solution of methyl (2R)-3-( { 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl }
amino)-2-hydroxypropanoate (0.020 g, 0.054 mmol) in acetonitrile (0.8 mL) and the solution heated to 50 C for three days. After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide (5R)-3-{3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl}-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-{ 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl }-2-oxo-1,3-oxazolidine-5-carboxylate (0.021 g, 0.054 mmol) in 0.5 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5%
MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M-H]- = 380 1H NMR (300 MHz, CD3CN): 3.96 (dd, J= 9, 6 Hz, IH), 4.18 (m, 3H), 4.42 (m, 2H), 4.80 (s, 111), 4.93 (dd, J= 10, 6 Hz, 1H), 6.16 (br s, IH), 6.70 (br s, 1H), 7.12 (dd, J= 10, 2 Hz, 2H) Intermediates for the synthesis of example 4 are prepared as follows.
I. Preparation of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-one A solution of DMSO (0.84 mL, 12 mmol) in dichloromethane (10 mL) is added to a cooled (-65 C) solution of oxallyl chloride (3.0 mL, 6.0 mmol) in dichloromethane (20 mL).
After stirring for 25 minutes, a solution of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-ol (1.25 g, 5.4 mmol) in 20 mL of 5% DMSO-dichloromethane is added dropwise. The reaction mixture is stirred for 30 minutes at -60 C and then treated with triethylamine (3.7 mL, 27 mmol) and allowed to warm to room temperature. After stirring for 4 hours, the reaction mixture is poured into water, the layers separated and the aqueous phase extracted with more dichloromethane. The combined organic phases washed with saturated NaHCO3, brine, and dried (MgSO4), filtered and concentrated. The residue is purified by column chromatography (0-30% ethyl acetate-hexane) to provide the title compound.
'H NMR (300 MHz, CDCl3): 5.17 (tr, J= 1 Hz, 4H), 7.80 (dd, J = 8, 2 Hz, 2H) II. Preparation of 1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)azetidin-3-ol (Trifluoromethyl)trimethylsilane (0.11 mL, 0.75 mmol) and then tetrabutylammonium fluoride (0.028 mL of a 1.0 M solution, 0.028 mmol) is added to a THF
(3.5 mL) solution of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-one (0.16 g, 0.70 mmol) cooled to 0 C. After warming to room temperature and stirring for 5 hours, saturated ammonium chloride solution (1.2 mL) and tetrabutylammonium fluoride (l.l mL of a 1.0 M
solution, 1.1 mmol) are added and the reaction mixture stirred for another hour. Ethyl acetate and water are then added, the layers separated, and the aqueous phase extracted with more ethyl acetate.
Combined organic phases are washed with water, brine, and dried (MgSO4), filtered and concentrated. The crude residue is purified by preparative TLC (20% ethyl acetate-hexane) to afford the title compound.
'H NMR (300 MHz, CDCl3): 2.84 (s, 1H), 4.40 (d, J = 10 Hz, 2H), 4.68 (d, J =
Hz, 2H), 7.74 (dd, J = 8, 2 Hz, 2H) IIT. Preparation of methyl (2R)-3-({3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl } amino)-2-hydroxypropanoate A solution of 1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)azetidin-3-ol (0.027 g, 0.091 mmol) in 2 mL of methanol containing 10% Pd/C (0.020 g) is stirred under an atmosphere of hydrogen. After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2,6-difluorophenyl)-3-(trifluoromethyl)azetidin-3-ol which is used directly in the next step.
A solution of 1-(4-amino-2,6-difluorophenyl)-3-(trifluoromethyl)azetidin-3-ol (0.091 mmol) in acetonitrile (0.3 mL) is treated with (R)-methyl glycidate (0.014 g, 0.14 mmol) and lithium triflate (0.022 g, 0.14 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 2.78 (br s, 1H), 3.04 (br s, 1H), 3.30-3.45 (m, 2H), 3.81 (s, 3H), 3.91 (br s, 1H), 4.06 (d, J = 10 Hz, 2H), 4.38 (app d, J= 10 Hz, 3H), 6.16 (dd, J = 10, 2 Hz, 2H) Example 5 Preparation of (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide ~ \ l NH2 1,1'-Carbonyldiimidazole (0.14 g, 0.83 mmol) is added to a solution of methyl (2R)-3-{[4-(3,3-difluoroazetidin-l-yl)-3-fluorophenyl]amino}-2-hydroxypropanoate (0.13 g, 0.43 mmol) in acetonitrile (5 mL) and the solution heated to 50 C for three days.
After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide methyl (5R)-3-[4-(3,3-difluoroazetidin-I-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.10 g, 0.31 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichlorometliane) to afford the title compound.
MS (m/z): [M+H7+ = 316 'H NMR (300 MHz, CD3CN): 4.02 (dd, J= 9, 6 Hz, 1H), 4.17-4.32 (m, 5H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.17 (br s, 1H), 6.63 (m, 1H), 6.70 (br s, 1H), 7.12 (m, 111), 7.42 (dd, J
= 15, 3 Hz, 1H) Intermediates for the synthesis of example 5 are prepared as follows.
I. Preparation of methyl (2R)-3-{[4-(3,3-difluoroazetidin-l-yl)-3-fluorophenyl]amino}-2-hydroxypropanoate A solution 1-(2-fluoro-4-nitrophenyl)-3,3-difluoroazetidine (0.19 g, 0.84 mmol) in 10 mL of methanol containing 10% Pd/C (0.020 g) is stirred under an atmosphere of hydrogen.
After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2-fluorophenyl)-3,3-difluoroazetidine which is used directly in the next step.
A solution 1-(4-amino-2-fluorophenyl)-3,3-difluoroazetidine (0.84 mmol) in acetonitrile (5 mL) is treated with (R)-methyl glycidate (0.13 g, 1.3 mmol) and lithium triflate (0.21 g, 1.3 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.25-3.50 (m, 4H), 3.78 (s, 3H), 4.18 (m, 4H), 4.36 (m, 1H), 6.43 (m, 3H) Example 6 Preparation of (5R)-N-methyl-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide H
p N-1 D
Methylamine (1.0 mL of a 2.0 M solution, 2.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.030 g, 0.091 mmol) in 0.5 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (3% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 330 'H NMR (300 MHz, CD3CN): 2.73 (d, J= 3 Hz, 3H), 3.98 (m, IH), 4.16-4.32 (m, 5H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.63 (m, 1H), 6.96 (br s, 1H), 7.14 (m, 1H), 7.43 (dd, J
15,3 Hz, 1H) Example 7 Preparation of (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl)-2-oxo-1,3-oxazolidine-5-carboxamide F
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.12 g, 0.39 mmol) and stirred at room temperature. After an hour, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 295 1H NMR (300 MHz, d6-DMSO): 1.82-1.92 (m, 2H), 2.55-2.61 (m, 2H), 2.98 (m, 1H), 3.95-4.08 (m, 2H), 4.24 (tr, J= 9 Hz, 1H), 4.98-5.03 (m, 1H), 5.11 (d, J= 6 Hz, 1H), 7.30-7.35 (m, 2H), 7.42 (d, J = 12 Hz, 1H) 7.60 (s, 1H), 7.84 (s, 1H) Intermediates for the synthesis of example 7 are prepared as follows.
I. Preparation of 3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)aniline A solution of benzyl3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenylcarbamate (1.2 g, 2.79 mmol) in 25 mL of methanol containing 20%
Pd(OH)2/C (0.3 g) is stirred under an atmosphere of hydrogen. After 4 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide the title compound, which is used directly in the next step.
MS (m/z): [M+H]+ = 296 'H NMR (300 MHz, CDC13): 0.067 (s, 6H), 0.89 (s, 9H), 1.94-2.01 (m, 2H), 2.58-2.63 (m, 2H), 2.94 (m, 1H), 3.45 (s, 2H), 4.19 (m, 1H), 6.29 (dd, J= 12, 2 Hz, 1H), 6.40 (dd, J= 9, 2 Hz, 1H) 6.99 (tr, J= 9 Hz, 1H) IC. Preparation of methyl (5R)-3-[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate A solution of 3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)aniline (0.83 g, 2.8 mmol) in acetonitrile (10.0 mL) is treated with (R)-methyl glycidate (0.43 g, 4.2 mmol) and lithium triflate (0.66 g, 4.2 mmol), heated to 60 C for 16 hours and then cooled and concentrated to provide methyl (2R)-3-{[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]amino }-2-hydroxypropanoate that is used in the next step without further purification.
1,1'-Carbonyldiimidazole (0.9 g, 5.6 mmol) is added to a solution of methyl (2R)-3-{ [3-fluoro-4-(3-{ tert-butyldimethylsilyloxy }-cyclobutyl)phenyl]amino } -2-hydroxypropanoate (1.1 g, 2.8 mmol) in acetonitrile (28 mL) and the solution heated to 65 C
for 16 hours. After cooling, ethyl acetate is added and the solution washed with dilute citric acid, saturated NaHCO3a brine, and dried (MgSO4), filtered and concentrated.
Column chromatography (0-4% MeOH-dichloromethane) afforded the title compound.
MS (m/z): [M+H] " = 424 'H NMR (300 MHz, CDC13): 0.043 (s, 6H), 0.87 (s, 9H), 1.93-2.03 (m, 2H), 2.61-2.69 (m, 2H), 3.03 (m, 1H), 3.84 (s, 3H), 4.06-4.11 (m, 1H), 4.21-4.28 (m, 2H), 5.02-5.07 (m, 1H), 7.11 (dd, J = 9, 2 Hz, 1H), 7.22 (tr, J = 9 Hz, 1H), 7.33 (dd, J = 12, 2 Hz, 1H) III. Preparation of methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate Hydrogen fluoride triethylamine complex (0.58 mL, 3.54 mmol) is added to a THF
(12.0 mL) solution of methyl (5R)-3-[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.5 g, 1.18 mmol) at room temperature. After 5 hours, the solution is treated with dilute NaHCO3 dropwise and extracted with dichloromethane. The organic extracts are washed with brine, dried (MgSO4), filtered, and concentrated. Purification by column chromatography (0-4% MeOH-dichloromethane) afforded the title compound.
MS (m/z): [M+H]+ = 310 1H NMR (300 MHz, CDC13): 1.93-2.03 (m, 2H), 2.70-2.79 (m, 2H), 3.04-3.08 (m, 1H), 3.85 (m, 3H), 4.06-4.11 (m, 1H), 4.21-4.32 (m, 2H), 5.02-5.07 (m, 1H), 7.11-7.20 (m, 2H), 7.33 (dd, J= 12, 2 Hz, 1H) Example 8 Preparation of (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide O
O
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.107 g, 0.31 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]} = 334 iH NMR (300 MHz, CD3CN): 3.96 (m, 1H), 4.18 (m, 1H), 4.40-4.52 (m, 4H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.16 (br s, 1H), 6.70 (br s, 1H), 7.17 (dd, J= 10, 2 Hz, 2H) Intermediates for the synthesis of example 2 are prepared as follows.
1. Preparation of methyl (2R)-3-{ [4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl] amino } -2-hydroxypropanoate F \ / NH OMe A solution of 1-(2,6-difluoro-4-nitrophenyl)-3,3-difluoroazetidine (0.25 g, 1.0 mmol) in 2 mL of methanol containing 10% Pd/C (0.050 g) is stirred under an atmosphere of hydrogen. After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroaniline which is used directly in the next step.
A solution of 4-(3,3-difluoroazetidin-1-yl)-3,5-difluoroaniline (1.0 mmol) in acetonitrile (4 mL) is treated with (R)-methyl glycidate (0.185 g, 1.2 mmol) and lithium triflate (0.236 g, 1.5 mmol), heated to 70 C for 3 hours and then cooled and concentrated.
The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.17 (br s, 1H), 3.30-3.45 (m, 2H), 3.81 (s, 311), 3.91 (br s, 1 H), 4.39 (m, 5 H), 6.16 (dd, J = 10, 2 Hz, 2H) Example 3 Preparation of (5R)-3-[4-(3-methoxyazetidin-l-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide P--<~ NH2 n-Butyllithium solution (2.1 mL of a 1.6 M hexanes solution, 3.32 mmol) is added to a cooled (-78 C) solution of benzy13,5-difluoro-4-(3-methoxyazetidin-1-yl)phenylcarbamate (0.77 g, 2.21 mmol) in THF (11 mL). After 10 minutes, ethyl (2R)-2,3-epoxypropanoate (0.77 g, 6.63 mmol) is added and the solution allowed to warm to room temperature and stirred for 18 h. Saturated aqueous ammonium chloride is added to the reaction mixture and extracted with dichloromethane. The aqueous phase is acidified to pH 1 with 1N
HCl and extracted with dichloromethane twice. The combined organic phases are then dried (MgSO4), filtered and concentrated to provide crude (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid that is used directly in the next reaction.
(Trimethylsilyl)diazomethane solution (0.24 mL of a 2M diethylether solution, 0.48 mmol) is added to a solution of (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylic acid (0.24 mmol) in MeOH (0.5 mL). After stirring at room temperature for 2 hours, the reaction mixture is concentrated and treated with methanolic ammonia (1.0 mL of a 2.0 M solution, 2.0 mmol). After 24 hours, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 328 'H NMR (300 MHz, d6-DMSO): 3.20 (s, 3H), 3.84-3.95 (m, 3H), 4.14-4.27 (m, 4H), 4.98 (m, 1H), 7.22 (dd, J = 9, 2 Hz, 2H), 7.60 (br s, 1H), 7.83 (br s, 1H) Example 4 Preparation of (5R)-3-{3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl } -2-oxo-1,3-oxazolidine-5-carboxamide F
F
1,1'-Carbonyldiimidazole (0.018 g, 0.108 mmol) is added to a solution of methyl (2R)-3-( { 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl }
amino)-2-hydroxypropanoate (0.020 g, 0.054 mmol) in acetonitrile (0.8 mL) and the solution heated to 50 C for three days. After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide (5R)-3-{3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl}-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-{ 3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-l-yl]phenyl }-2-oxo-1,3-oxazolidine-5-carboxylate (0.021 g, 0.054 mmol) in 0.5 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5%
MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M-H]- = 380 1H NMR (300 MHz, CD3CN): 3.96 (dd, J= 9, 6 Hz, IH), 4.18 (m, 3H), 4.42 (m, 2H), 4.80 (s, 111), 4.93 (dd, J= 10, 6 Hz, 1H), 6.16 (br s, IH), 6.70 (br s, 1H), 7.12 (dd, J= 10, 2 Hz, 2H) Intermediates for the synthesis of example 4 are prepared as follows.
I. Preparation of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-one A solution of DMSO (0.84 mL, 12 mmol) in dichloromethane (10 mL) is added to a cooled (-65 C) solution of oxallyl chloride (3.0 mL, 6.0 mmol) in dichloromethane (20 mL).
After stirring for 25 minutes, a solution of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-ol (1.25 g, 5.4 mmol) in 20 mL of 5% DMSO-dichloromethane is added dropwise. The reaction mixture is stirred for 30 minutes at -60 C and then treated with triethylamine (3.7 mL, 27 mmol) and allowed to warm to room temperature. After stirring for 4 hours, the reaction mixture is poured into water, the layers separated and the aqueous phase extracted with more dichloromethane. The combined organic phases washed with saturated NaHCO3, brine, and dried (MgSO4), filtered and concentrated. The residue is purified by column chromatography (0-30% ethyl acetate-hexane) to provide the title compound.
'H NMR (300 MHz, CDCl3): 5.17 (tr, J= 1 Hz, 4H), 7.80 (dd, J = 8, 2 Hz, 2H) II. Preparation of 1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)azetidin-3-ol (Trifluoromethyl)trimethylsilane (0.11 mL, 0.75 mmol) and then tetrabutylammonium fluoride (0.028 mL of a 1.0 M solution, 0.028 mmol) is added to a THF
(3.5 mL) solution of 1-(2,6-difluoro-4-nitrophenyl)azetidin-3-one (0.16 g, 0.70 mmol) cooled to 0 C. After warming to room temperature and stirring for 5 hours, saturated ammonium chloride solution (1.2 mL) and tetrabutylammonium fluoride (l.l mL of a 1.0 M
solution, 1.1 mmol) are added and the reaction mixture stirred for another hour. Ethyl acetate and water are then added, the layers separated, and the aqueous phase extracted with more ethyl acetate.
Combined organic phases are washed with water, brine, and dried (MgSO4), filtered and concentrated. The crude residue is purified by preparative TLC (20% ethyl acetate-hexane) to afford the title compound.
'H NMR (300 MHz, CDCl3): 2.84 (s, 1H), 4.40 (d, J = 10 Hz, 2H), 4.68 (d, J =
Hz, 2H), 7.74 (dd, J = 8, 2 Hz, 2H) IIT. Preparation of methyl (2R)-3-({3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl } amino)-2-hydroxypropanoate A solution of 1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)azetidin-3-ol (0.027 g, 0.091 mmol) in 2 mL of methanol containing 10% Pd/C (0.020 g) is stirred under an atmosphere of hydrogen. After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2,6-difluorophenyl)-3-(trifluoromethyl)azetidin-3-ol which is used directly in the next step.
A solution of 1-(4-amino-2,6-difluorophenyl)-3-(trifluoromethyl)azetidin-3-ol (0.091 mmol) in acetonitrile (0.3 mL) is treated with (R)-methyl glycidate (0.014 g, 0.14 mmol) and lithium triflate (0.022 g, 0.14 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 2.78 (br s, 1H), 3.04 (br s, 1H), 3.30-3.45 (m, 2H), 3.81 (s, 3H), 3.91 (br s, 1H), 4.06 (d, J = 10 Hz, 2H), 4.38 (app d, J= 10 Hz, 3H), 6.16 (dd, J = 10, 2 Hz, 2H) Example 5 Preparation of (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide ~ \ l NH2 1,1'-Carbonyldiimidazole (0.14 g, 0.83 mmol) is added to a solution of methyl (2R)-3-{[4-(3,3-difluoroazetidin-l-yl)-3-fluorophenyl]amino}-2-hydroxypropanoate (0.13 g, 0.43 mmol) in acetonitrile (5 mL) and the solution heated to 50 C for three days.
After cooling, ethyl acetate is added and the solution washed with dilute citric acid, twice with dilute NaHCO3, brine, and dried (MgSO4), filtered and concentrated to provide methyl (5R)-3-[4-(3,3-difluoroazetidin-I-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate which is used without further purification.
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.10 g, 0.31 mmol) in 3 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichlorometliane) to afford the title compound.
MS (m/z): [M+H7+ = 316 'H NMR (300 MHz, CD3CN): 4.02 (dd, J= 9, 6 Hz, 1H), 4.17-4.32 (m, 5H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.17 (br s, 1H), 6.63 (m, 1H), 6.70 (br s, 1H), 7.12 (m, 111), 7.42 (dd, J
= 15, 3 Hz, 1H) Intermediates for the synthesis of example 5 are prepared as follows.
I. Preparation of methyl (2R)-3-{[4-(3,3-difluoroazetidin-l-yl)-3-fluorophenyl]amino}-2-hydroxypropanoate A solution 1-(2-fluoro-4-nitrophenyl)-3,3-difluoroazetidine (0.19 g, 0.84 mmol) in 10 mL of methanol containing 10% Pd/C (0.020 g) is stirred under an atmosphere of hydrogen.
After 2.5 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide 1-(4-amino-2-fluorophenyl)-3,3-difluoroazetidine which is used directly in the next step.
A solution 1-(4-amino-2-fluorophenyl)-3,3-difluoroazetidine (0.84 mmol) in acetonitrile (5 mL) is treated with (R)-methyl glycidate (0.13 g, 1.3 mmol) and lithium triflate (0.21 g, 1.3 mmol), heated to 70 C for 3 hours and then cooled and concentrated. The residue is purified by preparative TLC (2% MeOH-dichloromethane) to afford the title compound.
'H NMR (300 MHz, CDC13): 3.25-3.50 (m, 4H), 3.78 (s, 3H), 4.18 (m, 4H), 4.36 (m, 1H), 6.43 (m, 3H) Example 6 Preparation of (5R)-N-methyl-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide H
p N-1 D
Methylamine (1.0 mL of a 2.0 M solution, 2.0 mmol) is added to a solution of methyl (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.030 g, 0.091 mmol) in 0.5 mL of methanol. After 90 minutes, the solution is concentrated and the residue purified by preparative TLC (3% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 330 'H NMR (300 MHz, CD3CN): 2.73 (d, J= 3 Hz, 3H), 3.98 (m, IH), 4.16-4.32 (m, 5H), 4.93 (dd, J = 10, 6 Hz, 1H), 6.63 (m, 1H), 6.96 (br s, 1H), 7.14 (m, 1H), 7.43 (dd, J
15,3 Hz, 1H) Example 7 Preparation of (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl)-2-oxo-1,3-oxazolidine-5-carboxamide F
Methanolic ammonia (2.0 mL of a 2.0 M solution, 4.0 mmol) is added to methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.12 g, 0.39 mmol) and stirred at room temperature. After an hour, the solution is concentrated and the residue purified by preparative TLC (5% MeOH-dichloromethane) to afford the title compound.
MS (m/z): [M+H]+ = 295 1H NMR (300 MHz, d6-DMSO): 1.82-1.92 (m, 2H), 2.55-2.61 (m, 2H), 2.98 (m, 1H), 3.95-4.08 (m, 2H), 4.24 (tr, J= 9 Hz, 1H), 4.98-5.03 (m, 1H), 5.11 (d, J= 6 Hz, 1H), 7.30-7.35 (m, 2H), 7.42 (d, J = 12 Hz, 1H) 7.60 (s, 1H), 7.84 (s, 1H) Intermediates for the synthesis of example 7 are prepared as follows.
I. Preparation of 3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)aniline A solution of benzyl3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenylcarbamate (1.2 g, 2.79 mmol) in 25 mL of methanol containing 20%
Pd(OH)2/C (0.3 g) is stirred under an atmosphere of hydrogen. After 4 hours, the solution is filtered through celite with the aid of methanol and the filtrate concentrated to provide the title compound, which is used directly in the next step.
MS (m/z): [M+H]+ = 296 'H NMR (300 MHz, CDC13): 0.067 (s, 6H), 0.89 (s, 9H), 1.94-2.01 (m, 2H), 2.58-2.63 (m, 2H), 2.94 (m, 1H), 3.45 (s, 2H), 4.19 (m, 1H), 6.29 (dd, J= 12, 2 Hz, 1H), 6.40 (dd, J= 9, 2 Hz, 1H) 6.99 (tr, J= 9 Hz, 1H) IC. Preparation of methyl (5R)-3-[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate A solution of 3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)aniline (0.83 g, 2.8 mmol) in acetonitrile (10.0 mL) is treated with (R)-methyl glycidate (0.43 g, 4.2 mmol) and lithium triflate (0.66 g, 4.2 mmol), heated to 60 C for 16 hours and then cooled and concentrated to provide methyl (2R)-3-{[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]amino }-2-hydroxypropanoate that is used in the next step without further purification.
1,1'-Carbonyldiimidazole (0.9 g, 5.6 mmol) is added to a solution of methyl (2R)-3-{ [3-fluoro-4-(3-{ tert-butyldimethylsilyloxy }-cyclobutyl)phenyl]amino } -2-hydroxypropanoate (1.1 g, 2.8 mmol) in acetonitrile (28 mL) and the solution heated to 65 C
for 16 hours. After cooling, ethyl acetate is added and the solution washed with dilute citric acid, saturated NaHCO3a brine, and dried (MgSO4), filtered and concentrated.
Column chromatography (0-4% MeOH-dichloromethane) afforded the title compound.
MS (m/z): [M+H] " = 424 'H NMR (300 MHz, CDC13): 0.043 (s, 6H), 0.87 (s, 9H), 1.93-2.03 (m, 2H), 2.61-2.69 (m, 2H), 3.03 (m, 1H), 3.84 (s, 3H), 4.06-4.11 (m, 1H), 4.21-4.28 (m, 2H), 5.02-5.07 (m, 1H), 7.11 (dd, J = 9, 2 Hz, 1H), 7.22 (tr, J = 9 Hz, 1H), 7.33 (dd, J = 12, 2 Hz, 1H) III. Preparation of methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate Hydrogen fluoride triethylamine complex (0.58 mL, 3.54 mmol) is added to a THF
(12.0 mL) solution of methyl (5R)-3-[3-fluoro-4-(3-{tert-butyldimethylsilyloxy}-cyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.5 g, 1.18 mmol) at room temperature. After 5 hours, the solution is treated with dilute NaHCO3 dropwise and extracted with dichloromethane. The organic extracts are washed with brine, dried (MgSO4), filtered, and concentrated. Purification by column chromatography (0-4% MeOH-dichloromethane) afforded the title compound.
MS (m/z): [M+H]+ = 310 1H NMR (300 MHz, CDC13): 1.93-2.03 (m, 2H), 2.70-2.79 (m, 2H), 3.04-3.08 (m, 1H), 3.85 (m, 3H), 4.06-4.11 (m, 1H), 4.21-4.32 (m, 2H), 5.02-5.07 (m, 1H), 7.11-7.20 (m, 2H), 7.33 (dd, J= 12, 2 Hz, 1H) Example 8 Preparation of (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide O
O
Methanolic ammonia (1.0 mL of a 2.0 M solution, 2.0 mmol) is added to methyl (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.08 g, 0.25 mmol) and stirred at room temperature. After an hour, the solution is concentrated to afford the title compound.
MS (m/z): [M+H]+ = 309 'H NMR (300 MHz, CDC13): 1.93-2.02 (m, 2H), 2.67-2.73 (m, 2H), 3.15 (m, 1H), 3.25 (s, 3H), 3.87 (m, 1H), 4.17-4.29 (m, 2H), 4.94-4.99 (m, 1H), 5.61 (s, 1H), 6.55 (s, 1H), 7.10-7.22 (m, 2H), 7.36 (dd, J= 12, 2 Hz, 1H) Synthesis of example 8 is prepared as follows.
I. Preparation of methyl (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate II.
, O
O
Trimethyloxonium tetrafluoroborate (0.077 g, 0.52 mmol) is added to a cooled (0 C) solution of methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.16 g, 0.52 mmol) and 2,6-di-tert-butyl-4-methyl pyridine (0.21 g, 1.0 mmol) in dicloromethane (3.25 mL). After stirring at 4 C for 16 h, the reaction mixture is diluted with dichloromethane, washed with saturated NaHCO3 and brine, and dried (MgSO4), filtered and concentrated. The crude residue is purified by pTLC (4% MeOH-dichloromethane) to provide the title compound.
MS (m/z): [M+H]+ = 324 'H NMR (300 MHz, CDC13): 1.92-2.02 (m, 2H), 2.64-2.72 (m, 211), 3.11-3.18 (m, 1H), 3.24 (s, 3H), 3.81-3.89 (m, 4H), 4.06-4.11 (m, 1H), 4.24 (tr, J= 9 Hz, 1H), 5.02-5.06 (m, IH), 7.11 (dd, J = 9, 2 Hz, 1H), 7.21 (tr, J = 6 Hz, 1H), 7.34 (dd, J = 12, 2 Hz, 1H)
MS (m/z): [M+H]+ = 309 'H NMR (300 MHz, CDC13): 1.93-2.02 (m, 2H), 2.67-2.73 (m, 2H), 3.15 (m, 1H), 3.25 (s, 3H), 3.87 (m, 1H), 4.17-4.29 (m, 2H), 4.94-4.99 (m, 1H), 5.61 (s, 1H), 6.55 (s, 1H), 7.10-7.22 (m, 2H), 7.36 (dd, J= 12, 2 Hz, 1H) Synthesis of example 8 is prepared as follows.
I. Preparation of methyl (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate II.
, O
O
Trimethyloxonium tetrafluoroborate (0.077 g, 0.52 mmol) is added to a cooled (0 C) solution of methyl (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxylate (0.16 g, 0.52 mmol) and 2,6-di-tert-butyl-4-methyl pyridine (0.21 g, 1.0 mmol) in dicloromethane (3.25 mL). After stirring at 4 C for 16 h, the reaction mixture is diluted with dichloromethane, washed with saturated NaHCO3 and brine, and dried (MgSO4), filtered and concentrated. The crude residue is purified by pTLC (4% MeOH-dichloromethane) to provide the title compound.
MS (m/z): [M+H]+ = 324 'H NMR (300 MHz, CDC13): 1.92-2.02 (m, 2H), 2.64-2.72 (m, 211), 3.11-3.18 (m, 1H), 3.24 (s, 3H), 3.81-3.89 (m, 4H), 4.06-4.11 (m, 1H), 4.24 (tr, J= 9 Hz, 1H), 5.02-5.06 (m, IH), 7.11 (dd, J = 9, 2 Hz, 1H), 7.21 (tr, J = 6 Hz, 1H), 7.34 (dd, J = 12, 2 Hz, 1H)
Claims (16)
1. A compound of formula I
or a pharmaceutically acceptable salt thereof wherein:
W is O, or S;
Y1, Y2, Y3, Y4 are independently CH, or CF;
Z is CH, or N;
R1 and R2 are independently (a) -H, (b) halo, (c) -CN, (d) -C(=W)NR3R4 (e) -(C=O)C1-6alkyl, (f) -(C=O)C3-8cycloalkyl, (g) -COOH, (h) -C1-6alkyl, (i) -WC1-6alkyl, (j) -C3-8cycloalkyl, (k) -OC3-8cycloalkyl, or (l) R1 and R2 taken together form =O, =N-OH, =N-OC1-4alkyl, =CH-CN;
R3 is -H, -C1-6alkyl, or -OC1-6alkyl;
at each occurrence, C1-6alkyl, or C3-8cycloalkyl is optionally substituted with CF3, 1-3 halo, OH, OC1-4alkyl, CN, N3, O(C=O)C1-4 alkyl, C3-6cycloalkyl, NH2, NHC(=O)C1-4 alkyl, or C(=O)C1-4 alkyl; and n is 0, 1, or 2.
or a pharmaceutically acceptable salt thereof wherein:
W is O, or S;
Y1, Y2, Y3, Y4 are independently CH, or CF;
Z is CH, or N;
R1 and R2 are independently (a) -H, (b) halo, (c) -CN, (d) -C(=W)NR3R4 (e) -(C=O)C1-6alkyl, (f) -(C=O)C3-8cycloalkyl, (g) -COOH, (h) -C1-6alkyl, (i) -WC1-6alkyl, (j) -C3-8cycloalkyl, (k) -OC3-8cycloalkyl, or (l) R1 and R2 taken together form =O, =N-OH, =N-OC1-4alkyl, =CH-CN;
R3 is -H, -C1-6alkyl, or -OC1-6alkyl;
at each occurrence, C1-6alkyl, or C3-8cycloalkyl is optionally substituted with CF3, 1-3 halo, OH, OC1-4alkyl, CN, N3, O(C=O)C1-4 alkyl, C3-6cycloalkyl, NH2, NHC(=O)C1-4 alkyl, or C(=O)C1-4 alkyl; and n is 0, 1, or 2.
2. A compound of claim 2 wherein Y1 and Y3 are independently CH or CF; and Y2 and Y4 are CH.
3. A compound of claim 2 wherein R1 and R2 are independently H, F, OH, OC1-2alkyl, C1-2alkyl, or CF3.
4. A compound of claim 2 wherein R3 is H or CH3.
5. A compound of claim 2 which is (1) (5R)-3-[3,5-difluoro-4-(3-fluoroazetidin-1-yl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (2) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (3) (5R)-3-[4-(3-methoxyazetidin-1-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (4) (5R)-3-{3,5-difluoro-4-[3-hydroxy-3-(trifluoromethyl)azetidin-1-yl]phenyl}-2-oxo-1,3-oxazolidine-5-carboxamide, (5) (5R)-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (6) (5R)-N-methyl-3-[4-(3,3-difluoroazetidin-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (7) (5R)-3-[3-fluoro-4-(3-hydroxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (8) (5R)-3-[3-fluoro-4-(3-methoxycyclobutyl)phenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, (9) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidine-5-carboxamide, or (10) (5R)-3-[4-(2,2-dioxido-2-thia-6-azaspiro[3.3]hept-6-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-1,3-oxazolidine-5-carboxamide.
6. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. A method for treating bacteria infections comprising administering to a mammal being treated a pharmaceutically effective amount of the compound of claim 1.
8. The method of claim 7 wherein the compound of claim 1 is administered orally.
9. The method of claim 7 wherein the compound of claim 1 is administered parenterally, topically, rectally, or intranasally.
10. The method of claim 7 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.
11. The method of claim 7 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.
12. The bacteria infection of claim 7 which is ear infections, eye infections, respiratory tract infections, skin and skin structure infections, bacterial endocarditis, osteomyelitis, endocarditis or diabetic foot.
13. The bacteria infection of claim 7 which is caused by gram-positive bacteria, gram negative bacteria, anaerobic organisms, and acid-fast organisms.
14. The bacteria infection of claim 7 which is caused by bacteria comprising staphylococci, streptococci, Enterococci, Haemophilus, Moraxella, bacteroides, clostridia, Mycobacteria, or Chlamydia.
15. The bacteria of claim 14 wherein staphylococci is S. aureus and S.
epidermidis;
wherein streptococci is S. pneumoniae of S. pyogenes; wherein Enterococci is E.
faecalis; wherein Haemophilus is H. influenzae; wherein Moraxella is M.
catarrhalis; and wherein Mycobacteria is M. tuberculosis; or Mycobacterium avium.
epidermidis;
wherein streptococci is S. pneumoniae of S. pyogenes; wherein Enterococci is E.
faecalis; wherein Haemophilus is H. influenzae; wherein Moraxella is M.
catarrhalis; and wherein Mycobacteria is M. tuberculosis; or Mycobacterium avium.
16. The bacteria infections of claim 7 which is caused by multi-drug resistant S. aureus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69673505P | 2005-07-06 | 2005-07-06 | |
US60/696,735 | 2005-07-06 | ||
PCT/IB2006/001835 WO2007004037A1 (en) | 2005-07-06 | 2006-06-26 | Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2614105A1 true CA2614105A1 (en) | 2007-01-11 |
Family
ID=37309094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002614105A Abandoned CA2614105A1 (en) | 2005-07-06 | 2006-06-26 | Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1902048A1 (en) |
JP (1) | JP2009500389A (en) |
CA (1) | CA2614105A1 (en) |
WO (1) | WO2007004037A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058423A2 (en) | 2008-11-20 | 2010-05-27 | Panacea Biotec Ltd. | Novel antimicrobials |
MX2012000231A (en) | 2009-06-26 | 2012-03-07 | Panacea Biotec Ltd | Novel azabicyclohexanes. |
ES2592518T3 (en) | 2011-10-13 | 2016-11-30 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
US9085568B2 (en) | 2011-10-13 | 2015-07-21 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
EP2765859B1 (en) | 2011-10-13 | 2017-01-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
AU2016295165B2 (en) * | 2015-07-17 | 2021-04-22 | The Global Alliance For Tb Drug Development, Inc. | Substituted phenyloxazolidinones for antimicrobial therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0788498B1 (en) * | 1994-10-26 | 2001-08-16 | PHARMACIA & UPJOHN COMPANY | Phenyloxazolidinone antimicrobials |
US7141588B2 (en) * | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
AR038536A1 (en) * | 2002-02-25 | 2005-01-19 | Upjohn Co | N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES |
BRPI0413838A (en) * | 2003-08-25 | 2006-10-24 | Warner Lambert Co | antimicrobial aryloxazolidinone compounds |
-
2006
- 2006-06-26 JP JP2008520016A patent/JP2009500389A/en active Pending
- 2006-06-26 EP EP06779819A patent/EP1902048A1/en not_active Withdrawn
- 2006-06-26 CA CA002614105A patent/CA2614105A1/en not_active Abandoned
- 2006-06-26 WO PCT/IB2006/001835 patent/WO2007004037A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2007004037A1 (en) | 2007-01-11 |
JP2009500389A (en) | 2009-01-08 |
EP1902048A1 (en) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0717738B1 (en) | Substituted oxazine and thiazine oxazolidinone antimicrobials | |
US5688792A (en) | Substituted oxazine and thiazine oxazolidinone antimicrobials | |
CA2614105A1 (en) | Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents | |
JP5662940B2 (en) | New antimicrobial agents | |
KR20020062332A (en) | Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent | |
US20090137553A1 (en) | Thiazepine Oxazolidinones as Antibacterial Agents | |
EP1899331B1 (en) | Homomorpholine oxazolidinones as antibacterial agents | |
CA2576041A1 (en) | Oxazolidinones containing oxindoles as antibacterial agents | |
US7435751B2 (en) | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | |
WO2007004049A1 (en) | Oxazolidinones containing azetidine as antibacterial agents | |
WO2007004032A1 (en) | Oxazolidiones containing cyclobutane as antibacterial agents | |
CA2637811A1 (en) | Benzisoxazole oxazolidinones as antibacterial agents | |
US20060229348A1 (en) | Oxindole oxazolidinone as antibacterial agent | |
CA2637158A1 (en) | Oxazolidinones containing oxindoles as antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |